Liver protein TREM-1 may predict steroid response in alcoholic hepatitis
NCT ID NCT07176741
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks at whether measuring a protein called TREM-1 in liver tissue can help doctors better predict how patients with severe alcoholic hepatitis will do. Researchers will compare TREM-1 levels in 300 people—half with alcoholic hepatitis and half with other liver diseases—using stored biopsy samples. The goal is to see if TREM-1 can guide treatment decisions, like who should get steroids or be considered for a liver transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple tissue test that helps doctors predict which patients will respond to steroids and who might need a liver transplant sooner.
- What could go wrong
- This is an early, observational study using stored tissue samples. It may not prove that TREM-1 is better than existing blood tests, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?